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A b s t r a c t
Background: Arterial hypertension is a common disorder that affects around 9 million adults in Poland. Single-pill combina-
tions (SPCs) for the treatment of arterial hypertension have significant advantages over the free combinations, resulting in 
lower risk of cardiovascular events and lower consumption of medical resources. The current ESC/ESH 2013 guidelines for 
the first time recommend treatment with a combination of thiazide-like diuretic with calcium channel blocker. Currently, no 
such combination is reimbursed from public funds in Poland. 
Aim: To assess the economic value of treatment with SPC of indapamide and amlodipine (Tertens-AM®) for hypertensive 
patients compared with free combination therapy (FC), in the Polish setting.
Methods: As there are currently no published data directly estimating the additional effect of using indapamide + amlo-
dipine SPC vs. FC, two extreme approaches are presented: with difference in effectiveness due to improved adherence 
to the treatment estimated from published studies on other molecules used in hypertension such as SPCs and FCs — the 
base-case approach (1); and assuming no difference of effectiveness or adherence between SPC and FC of indapamide and 
amlodipine — the conservative approach (2). Modelling was carried out based on the Markov process in lifetime horizon. 
In the base-case approach, with the difference in effectiveness between SPC and FC, it was assumed that the differences in 
compliance translate into the differences in systolic blood pressure. Patients’ characteristics were correlated with the risk of 
events associated with cardiovascular disease, based on the prediction algorithms from the Framingham Heart Study. Costs 
were considered from a National Health Fund (NHF) perspective and NHF and patient’s perspective, and therefore direct 
medical costs were only included. 
Results: The treatment with SPC of indapamide and amlodipine in place of FC resulted in 7.6 additional days of life in full 
health and longer overall patient survival by 2.9 days. The replacement of FC with SPC would result in national savings from 
both NHF perspective and NHF and patient’s perspective, irrespective of the assumption of the difference in adherence 
between SPC and FC. The savings would amount to 1.602–3.954 million PLN and 16.498–19.186 million PLN from NHF 
perspective and NHF and patient’s perspective, respectively. 
Conclusions: The treatment with SPC of indapamide and amlodipine for hypertensive patients was found to be dominant 
over FC or at least less expensive than treatment with FC when the difference in effectiveness was neglected. The replacement 
of FC with SPC would result in savings from both NHF perspective and NHF and patient’s perspective.
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INTRODUCTION
Arterial hypertension affects around 9 million adults in Po-
land [1]. The prevalence, at 30% of undiagnosed hyperten-
sion and 9% of diagnosed but untreated hypertension, was 
revealed by preliminary results of the NATPOL 2011 study 
(data unpublished, personal communication, NATPOL 
2011 Group). The new hypertension guidelines published 
by the European Society of Cardiology/European Society of 
Hypertension (ESC/ESH) widely recommend treating patients 
with two different hypertensive drugs, introducing for the 
first time diuretic-calcium channel blocker combination [2]. 
For such therapy single-pill combinations (SPCs; also known 
as fixed-dose combinations indicating two or more active 
substances administrated in one formulation) have significant 
advantages over free combinations (FCs; active substances 
administrated at the same doses in separate formulations), 
i.e. higher persistence and compliance, simplification of the 
therapeutic scheme, stronger hypertensive effect, and lower 
therapy costs. The newly published experts’ consensus of the 
Polish Cardiac Society and the Polish Society of Hypertension 
strongly promote SPC over FC, underlying better compliance, 
persistence, and adherence to treatment when using SPC and 
not FC on a regular basis. This paper advises Polish doctors 
to use SPC preferably and as such is unique in Europe [3].
Despite the above advantages of SPC over FC [4], 
resulting in lower risk of cardiovascular events and lower 
consumption of medical resources [5–7], and contrary to 
experts’ consensus, widespread use of SPC is uncertain. 
Only certain SPCs for the treatment of arterial hypertension 
are reimbursed in Poland (amiloride + hydrochlorothiazide, 
candesartan + hydrochlorothiazide, cilazapril + hydrochlo-
rothiazide, lisinopril + amlodipine, lisinopril + hydrochloro-
thiazide, losartan + hydrochlorothiazide, perindopril + am-
lodipine, perindopril + indapamide, ramipril + felodipine, 
ramipril + hydrochlorothiazide, telmisartan + hydrochloro-
thiazide, valsartan + hydrochlorothiazide). However, none 
of them contains a combination of thiazide-like diuretic and 
calcium channel blocker. Although head-to-head clinical 
trials comparing the effects of indapamide or chlorthalidone 
with hydrochlorothiazide (HCTZ) are not available, indirect 
comparisons and post hoc analyses suggest that the use of 
chlorthalidone or indapamide is associated with a reduc-
tion in cardiovascular events [8], which is not the case for 
HCTZ. It is worth noting that the majority of SPCs containing 
the diuretic component currently reimbursed in Poland are 
based on hydrochlorothiazide, which is not reimbursed as 
a separate treatment option; it is also noted as inferior com-
pared to indapamide by some guidelines (e.g. the National 
Institute for Health and Clinical Excellence, www.nice.org.
uk/guidance/CG127).  
The SPC of indapamide and amlodipine was examined 
in our study. The only medicine registered in Poland con-
taining SPC of indapamide and amlodipine is Tertens-AM® 
(Les Laboratoires Servier), which is available in two dosages: 
1.5 mg of indapamide + 5 mg of amlodipine and 1.5 mg of 
indapamide + 10 mg of amlodipine. According to the annual 
sales data provided by the National Health Fund (NHF, nfz.
gov.pl) 388,221,728 unit doses (5 mg or 10 mg) of amlodipine 
and 444,685,884 unit doses (1.5 mg) of indapamide were 
reimbursed by the NHF in 2013. Thus, the market potential 
of SPC of indapamide and amlodipine is up to 13 million units 
containing 30 doses in theory, and around one third of this 
value in practice. Hence an assessment of the economic value 
of the intervention, which could affect up to 350 thousand 
of individuals in Poland, was required. There was a need for 
economic evaluations of hypertension treatment with SPC of 
indapamide and amlodipine in the Polish setting.
To estimate the economic value of treatment with SPC 
of indapamide and amlodipine for hypertensive patients 
a cost–utility analysis was performed. 
As there is no data directly indicating that the SPC of 
indapamide and amlodipine will result in higher effectiveness 
in comparison with FC (data available for other SPCs only), 
the economic evaluation was carried out in the framework 
of two extreme assumptions: with difference in effectiveness 
due to difference in adherence to the treatment, and without 
difference of effectiveness or adherence between SPC and 
FC of indapamide and amlodipine.
METHODS
The population of this study complies with the registered 
indication for the use of Tertens-AM® (substitution treatment 
of patients with essential hypertension, who use indapamide 
and amlodipine at the same doses in separate formulations; 
summary of product characteristics, Terens-AM®, Poland).
Baseline patients’ characteristics were based on the results 
of the POZ-NAD study of 74,745 patients from Poland with 
the objective to characterise patients with arterial hyperten-
sion under hypertensive treatment [9]. Missing characteristics, 
as well as other inputs unavailable from the literature, were 
based on the results of a survey among experts from four 
medical centres in Poland (section A of Table 1).
Structure of economic model
Modelling was carried out based on a Markov-type cohort 
simulation process and implemented in Microsoft Excel 
2007 (Microsoft Corporation, Redmond, WA). The timeframe 
was a lifetime with a cycle length of a month during the first 
300 cycles and a year afterwards to balance the functionality 
and precision of the model. The observation of two hypo-
thetical cohorts of patients with arterial hypertension was 
performed. The starting point was the beginning of SPC treat-
ment in the study arm and continuation of treatment with FCs 
in the control arm. Thus the optimal moment of transition to 
the SPC was assumed in the study arm (normalisation of arte-
rial pressure or at least a significant reduction in the pressure 
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Table 1. Input variables of economic model
Variable Value (95% CI) Source and assumptions
A. Patients characteristics
Age at baseline [years] 59.70 (37.16–82.24) POZ-NAD [9]
Females 0.585 (0.472–0.693) POZ-NAD [9]
Nicotine users 0.221 (0.135–0.321) POZ-NAD [9]
Total cholesterol [mg/dL] 217.50 (133.81–301.19) POZ-NAD [9]
HDL cholesterol [mg/dL] 54.60 (14.22–94.98) POZ-NAD [9]
Patients with diabetes mellitus 0.233 (0.145–0.335) POZ-NAD [9]
Obese patients 0.437 (0.327–0.550) POZ-NAD [9]
Post-stroke patients at baseline 0.081 (0.031–0.152) POZ-NAD [9]
Patients with CVD at baseline 0.542 (0.429–0.653) POZ-NAD [9]
Patients with left ventricular hypertrophy 0.225 (0.069–0.440) Survey of experts from 4 medical centres
Patients requiring 5 mg dose of amlodipine  
(others: 10 mg/d)
0.409 (0.236–0.594) Survey of experts from 4 medical centres
Mean SBP at baseline [mmHg] 134.60 (SD 22.68) Iskenderov et al. [10]
B. Probability of CVD event modifiers
RR of stroke/TIA after other CVD event 1.55 (1.17–2.07) D’Agostino et al. [15] and  O’Donnell et al. [16] 
RR of other CVD event after stroke/TIA 1 Assumption of no impact since no data was identified
OR of subsequent CVD event 1.30 (1.10–1.60) Morrow et al. [17, 18] 
HR of subsequent stroke/TIA 2.04 (0.52–8.02) Meta-analysis of Howard et al. [19] and Bergh et al. [20]
C. Hypertensive drug utilisation measures (base-case scenario)
Probability of adherence (MPR or PDC ≥ 0.8)  
among patients treated with FCs
0.425 (0.315–0.538) Meta-analysis of FC arm of observational studies included 
in meta-analysis by Gupta et al. [21] updated to  
April 2014 (manuscript in preparation)
OR for adherence to treatment with SPCs vs. FCs 1.68 (1.41–2.00) Meta-analysis performed by Gupta et al. [21] updated  
with 6 studies (manuscript in preparation)
Mean MPR among adherent patients 0.831 (range: 0.8–1) Brixner et al. [22]
Mean MPR among non-adherent 0.388 (range: 0–0.8) Brixner et al. [22]
D. Determinants of effectiveness
Change in SBP on treatment with SPCs vs. FCs  
[mm Hg] (base-case analysis)
–4.10 (–9.80 to 1.50) Meta-analysis of 9 studies  
by Gupta et al. [21]
Change in SBP on treatment with SPCs vs. FCs  
[mm Hg] (sensitivity analysis)
–5.30 (–6.50 to –4.10) Results of recent large observational study  
by Bronsert et al. [25]
Change in SBP after subsequent medicine addition 
(ARBs) [mm Hg]
–8.74 (–10.05 to –7.44) Meta-analysis of Oparil et al. [12]  
and Calhoun et al. [13]
E. Health-related utility weights (base-case scenario)
Utility weights for general population Age-dependent Golicki et al. [26]
Utility decrement for hypertension 0.022 (range: 0–0.05) Sullivan et al. [33], Wang et al. [34], Burström et al. [35]
Utility weight for stroke/TIA 0.70 (0.67–0.73) Lunde et al. [27]
Utility weight for CVD other then stroke/TIA 0.73 (0.69–0.76) De Smedt et al. [28]; data for Polish patients only
F. Proportion of the main reason for hospitalisation of patients with CVD event other than stroke/TIA
Acute coronary syndrome 0.438 (0.403–0.541) Survey of experts from 4 medical centres in Poland
Angina pectoris or PAD 0.312 (0.284–0.320) Survey of experts from 4 medical centres in Poland
Congestive heart failure 0.250 (0.175–0.277) Survey of experts from 4 medical centres in Poland
Æ
www.kardiologiapolska.pl
Economic evaluation of Terens-AM®
771
under treatment with separate products of indapamide and 
amlodipine at doses equal to the ones in SPC). The simplified 
structure of the model is presented in Figure 1. Each cohort 
enters the model via ‘no CVD’ (cardiovascular disease), ‘post 
CVD’ (not stroke/TIA) (transient ischaemic attack), or ‘post 
stroke/TIA’ state depending on the patient’s condition at base-
line. In subsequent cycles, a patient can transfer to the clinical 
states associated with inpatient care of cardiovascular events; 
remain in its current state; transfer to states of history of cardio-
vascular events (after each event); or transfer to the absorbing 
state ‘Death’. The model allowed for the determination of the 
patient’s medical history, i.e. the proportion of patients with 
each CVD (stroke or TIA, acute coronary syndrome, angina 
pectoris, peripheral arterial disease, congestive heart failure), 
which enabled us to precisely estimate the health outcomes 
as well as costs associated with cardiovascular events.
Mean systolic blood pressure (SBP) at baseline was based 
on the trial of 89 patients with II degree arterial hypertension 
by Iskenderov et al. [10]. The average SBP after 24 weeks of 
treatment with FC of indapamide and amlodipine was used 
to inform the model, according to a defined starting point of 
modelling (after initial assessment of the efficacy and safety 
of the FC). The scenario considered differences in the ef-
fectiveness of SPC and FC assuming that the difference in 
adherence to the treatment and gradual loss of control over 
arterial pressure (as a result) would be apparent among pa-
tients from the compared arms — an increase in SBP would 
be observed with its magnitude dependent only on the level 
of adherence to treatment. The change of SBP each cycle was 
modelled with constant values of other biochemical measures 
(e.g. total cholesterol or high-density lipoprotein cholesterol) 
to eliminate potential secondary effects of arterial pressure 
reduction and hence the multiplication of the additional 
health effects of the SPC. The model considered observation 
of deterministic values of patients’ characteristics with the 
exception of SBP, which was observed as a stochastic vari-
able to assess the proportion of patients requiring treatment 
modification when a significant increase in arterial pressure 
Variable Value (95% CI) Source and assumptions
G. Other variables
Time to treatment modification, months 22 (14–30) Survey of experts from 4 medical centres in Poland
Probability of dying Age-dependent Life expectancy tables of Poland 2012 from  
Central Statistical Office (stat.gov.pl)
Days in hospital — stroke/TIA 7.20 DRG statistics for 2013 (prog.nfz.gov.pl); average length of 
hospitalisation for relevant DRGs
Days in hospital — other CVD events 4.51 DRG statistics for 2013 (prog.nfz.gov.pl); average length of 
hospitalisation for relevant DRGs
ARB — angiotensin receptor blocker; CI — confidence intervals; CVD — cardiovascular disease; DRG — Diagnosis Related Group; FC — free com-
bination; HDL — high density lipoprotein; HR — hazard ratio; MPR — medication possession ratio; OR — odds ratio; PAD — peripheral arterial 
disease; PDC — proportion of days covered; RR — risk ratio; SBP — systolic blood pressure; SD — standard deviation; SPC — single-pill combina-
tion; TIA — transient ischaemic attack
Table 1. (cont.) Input variables of economic model
Figure 1. Structure of the Markov model; CVD — cardiovascular disease; TIA — transient ischaemic attack
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due to non-adherence to treatment and no possibility to 
perform any action to improve the adherence to treatment 
(e.g. lack of knowledge, failure to provide information to the 
physician) was encountered. After a specific period of treat-
ment (22 months in base case) among the proportion of the 
cohort without control of arterial pressure (SBP > 140 mm Hg 
among patients younger than 60 years or > 150 mm Hg 
among others, according to the recommendations of the 
Eighth Joint National Committee [11]) the modification of 
treatment regiment was assumed. The addition of angiotensin 
receptor blocker (ARB) to current treatment was considered, 
mainly due to identification of efficacy data for triple therapy 
with ARBs [12, 13]. The addition of candesartan, eprosartan, 
irbesartan, losartan, telmisartan, or valsartan with the amount 
of each based on the national sales data of reimbursement 
medicines in 2013 (NHF Announcements) was modelled. 
For each cycle the patients’ characteristics were corre-
lated with the risk of events associated with CVD (stroke/TIA, 
other cardiovascular events, or death due to CVD), based on 
the prediction algorithms from the Framingham Heart Study 
[14]. Acknowledging the risk assessment tool relates primarily 
to patients without CVD at baseline, and in clinical practice 
CVD affects around 60% of the patients undergoing treatment 
for hypertension [9]; the increased risk of subsequent events 
associated with CVD were estimated based on the results of 
published studies (section B of Table 1) [15–20].
Utilisation of SPCs and FCs 
There are several estimators of adherence (compliance) to 
treatment, i.e. medication possession ratio (MPR) and propor-
tion of days covered (PDC). Each of these estimators has been 
interpreted as the proportion of doses taken as prescribed 
in our study. The standard definition of patient adherent to 
treatment was adopted, i.e. patients for whom MPR or PDC 
was calculated at ≥ 0.8.
To assess the difference in adherence to treatment with 
SPCs in comparison to FCs the meta-analysis performed by 
Gupta et al. [21] was updated. An additional search of medi-
cal databases was performed in April 2014. Seven additional 
studies were identified (details will be provided in a separate 
study). The updated meta-analysis indicated that the likeli-
hood of adherence to the treatment (MPR or PDC ≥ 0.8) with 
SPCs increases by an odds ratio (OR) of 1.68 in comparison 
with FCs (95% confidence intervals [CI] 1.41–2.00; manuscript 
in preparation). The probability of adherence to treatment 
with FCs was estimated via a meta-analysis of the relevant 
arm of observational studies incorporated in the updated 
Gupta et al. meta-analysis [21]. The probability of adherence 
in the SPCs arm was calculated using both variables. Using 
the probability of adherence in each arm and average MPR 
among adherent and non-adherent patients from Brixner et 
al. [22] (the only data source identified), the expected average 
proportion of days on recommended treatment with SPCs or 
FCs was calculated. The variables relating to the utilisation of 
hypertensive medicines are presented in section C of Table 1.
Whereas the base-case estimation method of consump-
tion of hypertensive medicines is limited by the availability 
of one source of information on average MPR/PDC among 
adherent and non-adherent patients, the direct estimation of 
average MPR/PDC during treatment with SPCs and FCs from 
Ferrario et al. [7], Dickson et al. (PMID: 18507275), and Yang 
et al. (PMID: 20629600) was tested in a sensitivity analysis. 
Determinants of effectiveness 
There are no data to quantitatively correlate the level of 
adherence to treatment with health outcomes in hyperten-
sive patients. Available information indicating the impact of 
SPC treatment on the risk of CVD events [6, 7] or indicat-
ing a difference in that risk between patients adherent and 
non-adherent to hypertensive treatment [23, 24] applies only 
to specific groups of patients and cannot be generalised to 
the total population of patients with arterial hypertension. We 
used SBP as the only predictor of different health outcomes 
between patients treated with SPCs and FCs mainly because 
results of the Framingham Heart Study, which indicated 
a higher prediction capability of this measure than diastolic 
blood pressure when assessing both as a continuous variables 
[14], and to create a framework for the assessment of SPCs in 
specific subgroups of patients with arterial hypertension (the 
algorithms used in our study could be easily incorporated in 
future simulations that could assess the value of SPCs in sub-
groups of patients). In the absence of empirical data on the 
impact of adherence on the achieved SBP (e.g. the impact 
of omission of an adequate number of doses of hypertensive 
medicines on the achieved SBP), the difference in SBP be-
tween treatment with SPCs and FCs was assessed using the 
results of the meta-analysis performed by Gupta et al. [21] in 
a base case. The update of the systematic review (April 2014) 
did not reveal any additional studies of SPCs and FCs with 
reduction of SBP as an endpoint. In sensitivity analysis the dif-
ference in SBP achieved under treatment with SPCs and FCs 
was assessed using the results of a recent large observational 
study by Bronsert et al. [25].
The impact of the addition of subsequent medicine was 
based on the results of a meta-analysis of two clinical trials 
that assessed the efficacy of triple therapy [12, 13]. Since the 
addition applied only to the share of patients with evaluated 
SBP, discretisation of continuous probability distribution of 
SBP was performed to assess the average SBP among patients 
successfully treated with SPCs or FCs and among patients 
requiring additional SBP-lowering boosters. The additional 
reduction of SBP resulting from ARB addition was applied 
to the others only. 
The variables related to the efficacy of hypertensive 
medicines in the reduction of SBP are presented in section D 
of Table 1.
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Health-related quality of life
Utilities for the health states represented in the model were 
based on a scale from 0 to 1, with 0 representing death and 
1 denoting a state of perfect health. Utility weights for the 
Polish general population reported by Golicki et al. [26] were 
used to assess the age-related deterioration in quality of life. 
When the impact of CVD on quality of life was assessed, 
data from studies of Polish patients or patients with similar 
characteristics, the results of measurements relating to the 
quality of life for at least several months from clinical events 
and the results relating to a total population of patients with 
a relevant clinical events (e.g. in the case of stroke — the 
quality of life of patients with stroke or TIA) were preferred. 
Thus initial reduction in quality of life due to CVD events was 
not considered in our analysis. 
The systematic review was performed to obtain informa-
tion on utility weights of hypertensive and CVD patients. The 
search yielded 475 records with at least 17 providing data 
that could be incorporated in the analysis (data not shown). 
Several quality of life studies and reviews were identified; 
however, the results of two studies [27, 28] were considered 
in base-case analysis according to the criteria described above 
(section E of Table 1).
Cost input and assumptions
Costs were considered from a NHF perspective, and NHF 
and patient’s perspective, and therefore direct medical costs 
were only included. Costs were presented in 2014 Polish 
zloty (PLN).
The cost of indapamide and amlodipine in FC treatment 
was based on the official, fixed-unit prices of reimbursed medi-
cines containing those substances at relevant doses (1.5 mg 
of indapamide and 5 mg or 10 mg of amlodipine per tablet), 
weighted by sales data in 2013 reported by the NHF (Polish 
Ministry of Health regulations and NHF announcements, 2014).
The cost of Tertens-AM® was based on the average retail 
price observed in May–July 2014 (www.osoz.pl, accessed July 
2014). In order to perform an analysis from the perspective 
of the NHF the reimbursement of SPC was assumed within 
a separate limit group and 30% patient co-payment, based on 
the regulations of the Reimbursement Law (Journal of Laws 
2011, no 122, item. 696, as amended) also confirmed by the 
recent recommendation of the President of the Polish Agency 
for Health Technology Assessment (HTA) (No. 205/2014, 
aotm.gov.pl). The calculation of the unit cost from the per-
spective of the NHF requires a drug that designate a refund 
limit, i.e. a maximal price of a unit in a specific group of medi-
cines. Based on the Act of May 12, 2011 for reimbursement 
of medicines, we assumed that the SPC containing 5 mg of 
amlodipine would set the limit, i.e. the SPC with a lower price 
of a unit dose and expected market share higher than 15%, 
according to the results of a survey among clinical experts 
and actual sales of 5 mg and 10 mg unit doses of amlodipine.
The average cost of reimbursed ARB weighted by sales 
data in 2013 was considered. The consumption of medical 
resources among patients with CVD was based on the results 
of a survey among experts from four medical centres in Po-
land. The unit cost of medical resources was based on the 
Polish tariffs for medical services from June 2014 according to 
relevant decrees of the President of the NHF (nfz.gov.pl) and 
actual unit prices of reimbursed medical products according 
to relevant decree of the Minister of Health.
The results of the cost analysis (Table 2) were validated 
by the results of published studies and/or country-specific 
statistics (prog.nfz.gov.pl).
Economic analysis
We calculated the differences in a lifetime’s discounted costs 
and benefits measured in life years and quality-adjusted life 
years (QALYs). The primary outcome of this simulation study was 
the incremental cost–utility ratio (ICUR) of the treatment with 
SPC of indapamide and amlodipine in place of FC therapy, ex-
pressed as an incremental cost per QALY saved. The ICUR was 
calculated as the difference in total costs from each economic 
perspective divided by the difference in effectiveness in QALYs.
We consider treatment with SPC to be ‘dominant’ if result-
ing in lower lifetime costs and higher QALYs in comparison to 
treatment with FC, and ‘dominated’ if resulting in higher total 
costs and lower QALYs (ICUR < 0 at both conditions). Willing-
ness to pay (WTP) to obtain additional QALY was established as 
three times the Gross Domestic Product per capita, following 
the regulations specific to Poland. In 2014, the threshold value 
was officially calculated at 111,381 PLN. This threshold was 
used to appraise the value of SPC therapy, when differences 
in effectiveness between SPC and FC were faced. 
In the conservative scenario assuming no difference in 
adherence to the treatment and thus no difference in effective-
ness, the difference in costs was used to appraise the value of 
SPC therapy (“cost-minimisation” approach).
All study results were presented per one patient in a life-
time horizon. The costs and health outcomes were discounted 
at 5% and 3.5% annual rates, respectively.
The analysis was performed following the recommenda-
tions of the Polish Agency of HTA Act of May 12, 2011 for 
reimbursement of medicines (Journal of Laws 2011, no 122, 
item 696) and the Regulation of the Ministry of Health on 
minimum requirements to be met by Health Technology As-
sessment (Journal of Laws 2012, item 388).
Sensitivity analysis
Sensitivity analyses to evaluate the robustness of our findings 
were conducted. 
One-way deterministic sensitivity analyses were per-
formed over the specified range of uncertainty derived 
from the literature (95% CI) or over the assumed range of 
uncertainty (Tables 1, 2). The one variable (change in SBP 
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achieved between SPCs and FCs treatment) was excluded 
from the one-way sensitivity analysis since the ‘no difference 
in effectiveness’ scenario was presented in base case.
Multivariate deterministic sensitivity analyses incorporat-
ing alternative sources of model input data (i.e. utility weights 
and SPCs/FCs drug utilisation measures) as well as a different 
structural assumption of the model (i.e. discounting at differ-
ent rates) were performed.
RESULTS
Base-case analysis
The results of base-case analysis are presented in Table 3. The 
treatment with SPC of indapamide and amlodipine in place 
of FC resulted in 7.6 additional days of life in full health and 
longer overall patient’s survival by 2.9 days. 
Despite the relatively small clinical effect per patient, 
the clinical benefits can be significant and clinically relevant 
if we take into account the entire population of hypertensive 
patients; moreover, the additional days of life are just and 
only due to the use of SPC in place of FC. What is more, the 
use of SPC instead of FC is more comfortable for patients and 
less costly, thus generating savings.
Despite the assumption regarding the difference in effec-
tiveness, the treatment with SPC of indapamide and amlodipine 
was found to be less expensive than treatment with FC from 
both the NHF perspective and the NHF and patient’s perspec-
tive. The lower average unit cost of SPC resulted in lower total 
cost from both economic perspectives in comparison with FC 
when the difference in effectiveness was excluded. Lower av-
erage unit cost of SPC and lower cost of CVD treatment, even 
with the higher utilisation of antihypertensive medicines due 
to higher adherence to treatment, resulted in lower total cost 
from both economic perspectives in comparison with FC when 
the difference in effectiveness was included.
Thus, the treatment with SPC of indapamide and am-
lodipine was found to be dominant over FC, or at least less 
expensive than treatment with FC, when the difference in 
effectiveness was ignored.
Sensitivity analyses
The sensitivity analyses confirmed the stability of the conclu-
sions of the primary analysis. The one-way sensitivity analyses 
of variables having the highest impact on ICER are presented 
in Figure 2. The scenarios of multivariate sensitivity analyses 
having the highest impact on results of model are presented 
in Table 4. Other variables and other scenarios of multivariate 
sensitivity analyses did not change the results of the model 
outside the range of ± 20% of the base-case results (data 
not shown).
None of the sensitivity analyses revealed SPC to not 
be cost-effective in comparison with FC with WTP at 
111,381 PLN. Alternative scenarios of SPC and FC utilisa-
Table 2. Mean values of cost variables (in PLN) with 95% confidence intervals in brackets
Variable NHF Patient
Hypertensive treatment (per month of treatment with 100% adherence):
1.5 mg indapamide and 5 mg amlodipine (Tertens-AM®; SPC) 12.83 5.50
1.5 mg indapamide and 10 mg amlodipine (Tertens-AM®; SPC) 12.83 7.11
1.5 mg indapamide (FC) 5.47 5.09
5 mg amlodipine (FC) 5.32 5.31
10 mg amlodipine (FC) 10.52 7.11
ARBs (subsequent line) 10.76 7.08




Stroke/TIA 5996.15 (4819.15–7299.82) 0
Acute coronary syndrome 7543.05 (4116.58–11,989.91) 0
Angina pectoris or PAD 2597.13 (1570.31–3878.07) 0
Congestive heart failure 4614.35 (1544.03–9335.37) 0
Additional post CVD treatment (per month):
Stroke/TIA 52.76 (26.99–87.02) 66.12 (41.49–96.39)
Acute coronary syndrome 67.35 (49.18–88.34) 51.08 (35.50–69.44)
Angina pectoris or PAD 58.19 (36.61–84.69) 34.46 (25.23–45.10)
Congestive heart failure 47.87 (33.29–65.04) 35.27 (27.44–44.06)
ARB — angiotensin receptor blocker; CVD — cardiovascular disease; FC — free combination; NHF — National Health Fund; PAD — peripheral 
arterial disease; SPC — single-pill combination; TIA — transient ischaemic attack
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tion (direct estimation of MPR/PDC for SPCs and FCs from 
studies comparing those treatments) resulted in higher total 
cost of SPC treatment than FC from the perspective of the 
NHF (by 109.07 PLN) with additional health benefit. The 
ICUR estimated for this scenario did not exceed the WTP in 
Poland, indicating that the SPC treatment was cost-effective 
in comparison to FC treatment in all scenarios (Table 4).
DISCUSSION
The present study has estimated, based on the literature 
data and results of surveys among experts, the cost–utility of 
arterial hypertension treatment with SPC of indapamide and 
amlodipine in comparison with FC treatment in Polish settings.
An obvious limitation of our analysis is the lack of data 
directly demonstrating that the SPC of indapamide and 
Table 3. Results of base-case analysis (discounted)
Endpoint SPC with higher  
adherence (1)
SPC with the same 
adherence (2)





Life years 14.4428 14.4348 14.4348 0.0080 0.0000
Quality-adjusted life years 9.4448 9.4240 9.4240 0.0208 0.0000
Cost from NHF perspective, in PLN:
SPC or FC 1218.26 1107.87 1197.01 21.25 –89.14
Other, direct medical 9868.59 10,050.92 10,050.92 –182.33 0.00
Total 11,086.85 11,158.79 11,247.93 –161.08 –89.14
Cost from NHF and patient’s perspective, in PLN:
SPC or FC 1830.92 1665.02 2186.71 –355.79 –521.69
Other, direct medical 14,264.55 14,492.47 14,492.47 –227.92 0.00
Total 16,095.47 16,157.49 16,679.18 –583.71 –521.69
FC — free combination; NHF — National Health Fund; SPC — single-pill combination
Figure 2. One-way sensitivity analyses of the effect of the seven key input variables on incremental cost–utility ratio from the 
perspective of the National Health Fund (NHF) (A) or NHF and patient (B). Negative values of incremental cost-utility ratio mean 
single-pill combination (SPC) dominates free combination (FC) comparator; CI — confidence interval; CVD — cardiovascular disease; 
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amlodipine results in higher effectiveness in comparison 
with FC (no clinical studies were identified that would have 
enabled a comparison of intervention taking into account 
aspects significant for public payer and/or patients, including 
adherence). Hence, the results of a meta-analysis for other 
SPCs were used in this analysis. However, the extremely 
conservative assumption of no difference in patients’ ad-
herence between the SPC and the FC comparator yielded 
essentially the same conclusions as the base-case analysis; 
therefore, the findings of our study seem very robust with 
respect to the clinical input. It is worth mentioning that the 
effectiveness results presented in the study could be related 
to the comparison of any SPC with FC; however, as we do 
not consider SBP achieved on the treatment with other FCs 
there could be some changes in the estimated number of 
QALY saved for SPCs of other substances (the algorithm used 
to obtain the amount of CVD events avoided is based on an 
absolute value of SBP, i.e. the sum of SBPs achieved with 
FC and ‘gain’ in SBPs from compliance boost). The cost of 
treatment differs between SPCs, so the results of our study 
could not be generalised to all SPCs.
Secondly, there was also no possibility to directly assess 
the influence of the analysed combined intervention on clini-
cally significant endpoints, including the risk of cardiovascular 
event occurrence or deaths due to hypertension. Therefore, 
we used the algorithm of conversion of the SBP to clinically 
significant endpoints. Additionally, there are no studies carried 
out in Polish settings, which assess the influence of all clinical 
events included in this analysis on life quality. In the absence 
of precise and cross-sectional data, the results of the survey 
were used to determine the medical resources used among 
the study population. Data received from clinical experts was 
confirmed by published studies. 
Despite the limitations, some results of our study, i.e. ex-
pected savings related to cost of cardiovascular events omitted 
as a result of the higher adherence to treatment with SPC in 
comparison to FC, are reflected by the results of retrospective 
observational studies conducted in other settings [5–7, 29].
The impact of adherence to hypertensive treatment on 
health care resources utilisation and/or health outcomes were 
confirmed by observational studies [23, 24] as well as simula-
tion studies [30, 31]. 
However, no prospective study was identified to date, 
which assesses the economic value of hypertensive treatment 
with SPC in comparison to FC. No economic evaluation was 
identified which compares the SPC with FC in any setting.
A meta-analysis of retrospective studies incorporating 
direct medical costs, adherence and persistence estimates 
Table 4. Results of key multivariate sensitivity analyses
Scenario With higher in adherence in SPC No difference in  
adherence SPC vs. FC
Difference in cost from 
perspective of NHF (NHF 
and patient), in PLN
Difference 
in QALY
Difference in cost 
from perspective 
of NHF (NHF and 
patient), in PLN
ICUR from  
perspective of NHF 
(NHF and patient)
Base-case scenario 0.0208 –161.08 (–583.71) Dominant (dominant) –89.14 (–521.69)
Alternative scenario of change in SBP on 
treatment with SPCs vs. FCs (Bronsert et 
al. [25])
0.0267 –217.22 (–655.84) Dominant (dominant) –89.14 (–521.69)
Alternative scenario of drug utilisation 
— direct estimation of MPR/PDC for SPCs 
and FCs from Ferrario et al. [7], Dickson 
et al. (PMID: 18507275), and Yang et al. 
(PMID: 20629600)
0.0208 109.07 (–105.82) 5241 PLN per QALY 
saved (dominant)
–73.96 (–432.88)
Alternative scenario of utilities  
(Ward et al. PMID: 17408535)
0.0183 –161.08 (–583.71) Dominant (dominant) –89.14 (–521.69)
Alternative scenario of utilities (QALY 
losses per event from Lindgren et al. 
PMID 17165074)
0.0475 –161.08 (–583.71) Dominant (dominant) –89.14 (–521.69)
Alternative scenario of utilities (utility 
decrements from Burström et al. [35])
0.0160 –161.08 (–583.71) Dominant (dominant) –89.14 (–521.69)
No discounting 0.0426 –326.91 (–1,067.54) Dominant (dominant) –153.87 (–900.59)
FC — free combination; ICUR — incremental cost-utility ratio; LY — life year; MPR — medication possession ratio; NHF — National Health Fund; 
PDC — proportion of days covered; PMID — PubMed-Indexed for MEDLINE; SBP — systolic blood pressure; SPC — single-pill combination;  
QALY — quality-adjusted life year
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among SPC and FC treatment was found [5]. Patients receiving 
SPC are more likely to be adherent to treatment (by 13.3%; 
95% CI 8.26–18.35%) with more than two times longer per-
sistence (RR 2.13; 95% CI 1.11–4.09) compared with FC. The 
influence of therapy (SPC or FC) on treatment costs was also 
proven (lower costs in the SPC group) [5].
Adherence and the risk of cardiovascular event occur-
rence in hypertensive patients treated with SPC of amlodipine 
and olmesartan, SPC of amlodipine and benazepril, or FC of 
amlodipine and ARB were assessed in study [7]. The results 
showed that in the FC group the risk of cardiovascular events 
occurrence is higher than in SPC of amlodipine and olmesar-
tan (HR 1.35, p < 0.001). In another study it was proven that 
SPC therapy results in a reduction of cardiovascular events by 
27% (95% CI 24–30%) compared with FC [6].
A meta-analysis of four studies, carried out in the year 
2007, indicated that patients on SPC therapy have a 24% (95% 
CI 19–29%) lower risk of being non-adherent compared with 
patients on FC therapy [29]. 
A limited number of studies confirmed the direct influ-
ence of SPC treatment instead of FC on the risk of cardiovas-
cular events or the risk of death due to cardiovascular events 
[6, 7]. Nevertheless, some observational studies and model-
ling results showed the influence of adherence on the risk of 
cardiovascular events and/or the risk of death due to CVD.
The results of a simulation study [30] indicate that rais-
ing of the average adherence to 70% results in a decrease 
of cardiovascular events by 1%. In another study [31] it was 
observed that with 100% adherence the risk of stroke, myo-
cardial infarction, kidney disease due to hypertension, and 
heart disease due to hypertension was reduced by 34%, 27%, 
37%, and 31%, respectively.
In a study including patients with hypertension, without 
CVD, a reduction of annual risk of CVD by 22% (95% CI 
13–30%) was observed among patients adherent to treat-
ment compared with non-adherent patients [23]. Similarly, 
in a study including patients with hypertension, without 
prior stroke [24], a reduction of risk of stroke and death by 
8% (95% CI 4–13%) and 7% (95% CI 4–10%), respectively, 
was observed in adherent patients compared with non-ad-
herent patients.
The improvement of hypertensive treatment in Poland 
undoubtedly results from greater use of SPC [32]. SPC medi-
cines with their additional clinical benefits in the form of bet-
ter adherence, stronger hypertensive effect, limited adverse 
events, simplification of treatment scheme, and lower costs, 
are becoming more and more popular among hypertensive 
patients [3].  
The results of our study show that the treatment with 
SPC of indapamide and amlodipine in place of FC results 
in higher effectiveness and lower costs from both economic 
perspectives. Even with the conservative assumption of 
equal effectiveness of SPC and FC, outcomes of economic 
evaluation remained favourable to SPC (lower cost from 
both perspectives).
In 2013, the NHF refunded around 116,466,518 daily 
doses of indapamide (2.5 mg/d) and amlodipine (5 or 10 mg/d) 
administrated in FC schemes. This amounted to 53.057 mil-
lion PLN from an NHF perspective and around 43.868 million 
PLN from a patients’ perspective.
The replacement of FC with SPC results in savings for 
both NHF perspective and NHF and patient’s perspective, 
irrespectively of the assumption of the difference in adherence 
between SPC and FC. When the difference in effectiveness 
is neglected, the savings would amount to 3.954 million PLN 
and 19.186 million PLN from the NHF perspective and from 
the NHF and patient’s perspective, respectively. When higher 
adherence to treatment with SPC is assumed, the total savings 
amount to 1.602 million PLN from the NHF perspective and 
16.498 million PLN from the NHF and patients’ perspective. 
The introduction of SPC of indapamide and amlodipine on 
the reimbursement list next to FC resulted also in avoidance 
of 598 cardiovascular events in the target patients’ population 
(calculated based on the average annual CVD events rate from 
the Markov model and population size expressed as a number 
of patients-years). It backs up the mentioned experts’ con-
sensus of the Polish Cardiac Society and the Polish Society of 
Hypertension promoting SPC over FC in clinical practice [3].
The Health Technology Assessment for SPC of indapam-
ide and amlodipine (Tertens-AM®) had already been appraised 
by the Polish HTA Agency, and the drug received a positive 
recommendation. The AHTAPol conclusions were based on 
an economic analysis, but the results presented in this paper 
differ from HTA documentation due to another cost input 
(different prices of Tertens-AM®) included in the analysis.
CONCLUSIONS
Arterial hypertension treatment with SPC of indapamide 
and amlodipine was found to be economically warranted, 
irrespective of the assumption of the economic model. The 
treatment with SPC dominated the FC when the difference in 
adherence to treatment and effectiveness were considered; 
SPC was less expensive than FC when the difference in ef-
fectiveness was neglected. 
Treatment with SPC of indapamide and amlodipine in 
comparison to FC generates significant national savings from 
both the public payer’s perspective and from the public 
payer’s and patient’s perspective, in the contemporary Polish 
setting. It could reduce the number of cardiovascular events 
among treated patients due to an increase in the adherence 
rate. Therefore reimbursement of this SPC from public funds 
is justified also from the budgetary point of view, on top of 
arguments focusing on clinical evidence, guidelines, and 
impact on patients’ adherence to therapy.
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S t r e s z c z e n i e
Wstęp: Nadciśnienie tętnicze jest powszechnym schorzeniem w Polsce i dotyczy 9 mln osób dorosłych. Terapia nadciśnie-
nia tętniczego produktami złożonymi (SPC) z dwóch lub więcej substancji cechuje się istotnymi korzyściami w porównaniu 
z politerapią (FC) składnikami produktu złożonego (tj. większe stosowanie się do zaleceń i wynikająca z tego lepsza kontrola 
nadciśnienia), które skutkują niższym ryzykiem wystąpienia zdarzeń sercowo-naczyniowych i mniejszym zużyciem zasobów 
medycznych. W aktualnych wytycznych ESC/ESH z 2013 r. po raz pierwszy zarekomendowano terapię skojarzoną diurety-
kiem i antagonistą kanału wapniowego. Obecnie żadne takie połączenie nie jest współfinansowane ze środków publicznych 
w Polsce. Jedynym zarejestrowanym w naszym kraju produktem złożonym indapamidu i amlodipiny jest Tertens-AM®, który 
jest dostępny w dawkach: 1,5 mg indapamidu + 5 mg amlodipiny oraz 1,5 mg indapamidu + 10 mg amlodipiny. Potencjalna 
wielkość rynku dla produktu złożonego indapamidu i amlodipiny, oszacowana na podstawie danych refundacyjnych Naro-
dowego Funduszu Zdrowia (NFZ), wynosi teoretycznie nawet do 13 mln jednostek zawierających 30 dawek, a w praktyce 
może osiągnąć jedną trzecią tej wartości (350 tys. osób w Polsce). 
Cel: Celem badania była ocena zasadności ekonomicznej leczenia produktem złożonym indapamidu i amlodipiny (Tertens-
-AM®) pacjentów z nadciśnieniem tętniczym w porównaniu z politerapią indapamidem i amlodipiną w Polsce.
Metody: Wobec braku opublikowanych danych bezpośrednio oceniających dodatkowy efekt kliniczny zastosowania pro-
duktu złożonego indapamidu i amlodipiny w miejsce politerapii tymi substancjami u pacjentów z nadciśnieniem tętniczym, 
w analizie ujęto dwa podejścia: pierwsze uwzględnia różnice w efektywności wynikające z lepszego stosowania się do zaleceń 
(adherence), oszacowane na podstawie opublikowanego badania dla innych molekuł stosowanych w terapii nadciśnienia 
— analiza podstawowa (1) oraz drugie zakładające brak różnic w efektywności lub stosowaniu się do zaleceń między SPC 
i FC indapamidu z amlodipiną — podejście konserwatywne (2). Populację badaną stanowili pacjenci zgodni z zarejestrowa-
nym wskazaniem do stosowania produktu Tertens-AM® (leczenie substytucyjne osób z nadciśnieniem tętniczym samoistnym, 
którzy stosują indapamid i amlodipinę w takich samych dawkach w oddzielnych preparatach). Wejściowe dane kliniczne 
oszacowano na podstawie literatury, a w przypadku ich braku wykorzystano odpowiedzi ekspertów z 4 ośrodków klinicznych 
w Polsce. Modelowanie przeprowadzono na podstawie modelu Markowa, w dożywotnim horyzoncie czasowym. Obserwacji 
poddano dwie hipotetyczne grupy (SPC i FC) z nadciśnieniem tętniczym. W modelu założono modyfikację schematu lecze-
nia (dodanie antagonisty receptora angiotensyny do aktualnego schematu terapii) w przypadku braku kontroli skurczowego 
ciśnienia tętniczego po założonym okresie czasu. Charakterystykę pacjentów skorelowano z ryzykiem zdarzeń związanych 
z chorobą układu sercowo-naczyniowego, wykorzystując algorytmy predykcji z badania Framingham Heart Study. W celu 
oceny różnicy w stosowaniu się do zaleceń między SPC i FC przeprowadzono aktualizację metaanalizy Gupta et al., która 
wykazała, że prawdopodobieństwo stosowania się do zaleceń jest większe w przypadku SPC w porównaniu z FC (iloraz szans: 
www.kardiologiapolska.pl780
OR = 1,68). Prawdopodobieństwo stosowania się do zaleceń w przypadku FC zostało określone na podstawie metaanalizy 
badań obserwacyjnych, natomiast w przypadku SPC wykorzystano analogiczne dane skorygowane o wartość OR. Z powodu 
braku danych umożliwiających ilościową korelację poziomu stosowania się do zaleceń z wynikami zdrowotnymi, uwzględniono 
ciśnienie skurczowe jako jedyny predyktor różnicy w wynikach zdrowotnych między pacjentami SPC i FC. Do oceny jakości 
życia wykorzystano dane dla populacji ogólnej w Polsce oraz informacje o redukcji jakości życia wynikającej z wystąpienia 
uwzględnionych w analizie zdarzeń klinicznych. Koszty oszacowano z perspektywy płatnika publicznego (NFZ) oraz płatnika 
publicznego i pacjenta. Wzięto pod uwagę tylko bezpośrednie koszty medyczne. W ocenie kosztów farmakoterapii amlodipiną 
i indapamidem uwzględniono wyłączenie preparaty refundowane w odpowiedniej dawce (1,5 mg w przypadku indapamidu 
i 5 lub 10 mg w przypadku amlodipiny). Koszt produktu Tertens-AM® określono na podstawie średniej ceny detalicznej w lipcu 
2014 r. Założono współfinansowanie ocenianego produktu w ramach osobnej grupy limitowej, z 30-procentową odpłatnością 
pacjenta do wysokości limitu finansowania. Zużycie zasobów medycznych przez chorych z analizowanej populacji określono 
na podstawie wyników badania kwestionariuszowego przeprowadzonego wśród ekspertów klinicznych z 4 ośrodków w Polsce. 
W ramach analizy ekonomicznej określono lata życia skorygowane o jakość oraz koszty całkowite z obu uwzględnionych 
perspektyw dla stosowania SPC i FC indapamidem oraz amlodipiną. 
Wyniki: Leczenie SPC indapamidu i amlodipiny w miejsce FC wiąże się z uzyskaniem dodatkowych 7,6 dnia życia w pełnym 
zdrowiu oraz dłuższym o 2,9 dnia przeżyciem. Stosowanie SPC okazało się tańsze w porównaniu z FC zarówno z perspektywy 
płatnika publicznego, jak i płatnika publicznego oraz pacjenta. Zastosowanie SPC w miejsce FC będzie się wiązać z oszczęd-
nościami z perspektywy płatnika publicznego oraz pacjenta, zarówno w przypadku braku uwzględnienia, jak i uwzględnienia 
różnic w skuteczności klinicznej między SPC i FC. Oszczędności wyniosą 1,602–3,954 mln PLN oraz 16,498–19,186 mln PLN, 
odpowiednio z perspektywy płatnika publicznego oraz pacjenta.
Wnioski: Stosowanie SPC indapamidu i amlodipiny u pacjentów z nadciśnieniem tętniczym dominuje nad FC, przy założeniu 
różnic w efektach zdrowotnych lub jest tańsze w odniesieniu do FC w przypadku pominięcia różnic w efektach zdrowotnych. 
Zastosowanie SPC w miejsce FC będzie się wiązać z oszczędnościami z perspektywy płatnika publicznego oraz pacjenta, 
zarówno w przypadku uwzględnienia, jak i braku uwzględnienia różnic w skuteczności klinicznej. 
Słowa kluczowe: indapamid, amlodipina, produkt złożony, ekonomika zdrowia, analiza kosztów-użyteczności, analiza 
wpływu na budżet
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